MoonLake Immunotherapeutics (MLTX) vs Rigel Pharmaceuticals, Inc. (RIGL)

MoonLake Immunotherapeutics and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. MoonLake Immunotherapeutics and Rigel Pharmaceuticals, Inc. are of similar size ($882.6M and $873.2M). MoonLake Immunotherapeutics has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. has the higher net margin (116.3% vs 0.00%) and the higher return on invested capital (16.5% vs 0.00%). Across the 14 metrics below, Rigel Pharmaceuticals, Inc. leads on 12 and MoonLake Immunotherapeutics on 2.

Valuation

Metric MLTX RIGL Biotechnology median
P/E n/m 2.60 8.50
P/S n/m 3.08 9.71
P/B 1.65 2.00 2.13
Price to free cash flow n/m 94.91 20.82
EV/EBITDA n/m 8.70 0.64
EV/Sales n/m 2.79 9.21
Earnings yield (40.21%) 38.44% (33.15%)
Free cash flow yield (31.91%) 1.05% (25.50%)

Profitability

Metric MLTX RIGL Biotechnology median
Gross margin 0.00% 91.39% 65.16%
Operating margin 0.00% 31.45% 0.00%
Net margin 0.00% 116.30% 0.00%
Free cash flow margin 0.00% 3.19% 0.00%
Return on equity (67.08%) 126.90% (56.36%)
Return on assets (51.00%) 88.46% (48.04%)
Return on invested capital 0.00% 16.48% 0.00%

Growth

Metric MLTX RIGL Biotechnology median
Revenue growth (TTM) — 3.31% 6.02%
EPS growth (last fiscal year) (86.77%) 1,867.68% 30.26%
Revenue growth, 5-year CAGR — 22.06% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLTX RIGL Biotechnology median
Debt to equity 0.23 0.00 0.00
Current ratio 12.56 1.94 4.72
Net debt to EBITDA 1.32 (1.05) 0.96

Dividend

Metric MLTX RIGL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MLTX RIGL Biotechnology median
Market cap 873.19m 882.62m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack